Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer

BACKGROUND


Biliary Tract Cancer (BTC)

- Aggressive cancer with a poor prognosis
- Heterogenous disease consisting of distinct subgroups
- Intra and extra-hepatic cholangiocarcinoma, gallbladder, or ampullary
- No approved agents exist for the first-line treatment of advanced BTC
- Current standard of care: gemcitabine + cisplatin
- Median overall survival (OS) 11.7 months (ABC-02)¹
- Resistance to chemotherapy is associated with poor survival
- Effective new agents and combinations are required


NUC-1031: A ProTide transformation of gemcitabine

- A new class of anti-cancer agents
- Overcomes key gemcitabine resistance mechanisms²
- Cellular uptake independent of nucleoside transporters (hENT1)
- Activation independent of deoxycytidine kinase (dCK)
- Protected from breakdown by cytidine deaminase (CDA)
- In comparison to gemcitabine, NUC-1031 has³:
- Greater plasma stability (t_{1/2} 8.3 hours vs 1.5 hours)
- Increased intracellular levels of active anti-cancer metabolite, dFdCTP (217x)
- Reduced toxic metabolites

NUC-1031 bypasses the key cancer resistance pathways of gemcitabine



NUC-1031



ERENCES: 1. Valle et al. N Engl J Med 2010; 362:1273-1281. 2. Slusarczyk et al. J Med Chem 2014; 57:1531-1542. 3. Blagden et al. Br J Cancer 2018; 119:815-822. 4. McNamara MG et al. 2020 REVIATIONS: BTC: biliary tract cancer OS: overall survival hENT1: human equilibrative nucleoside transporter 1 dCK: deoxycytidine kinase CDA: cytidine deaminase dFdCTP: diflu

Phase 1b ABC-08 study: NUC-1031 + cisplatin⁴

- Favorable safety profile that was tolerated over multiple cycles;
- Encouraging efficacy with activity across all BTC subtypes (44% ORR*)

- NUTIDE 121 **INCLUSION CRITERIA**
- Previously untreated histologically or cytologically-confirmed adenocarcinoma of the biliary tract (intra and extra-hepatic cholangiocarcinoma, gallbladder, or ampullary cancers) that is locally advanced, unresectable or metastatic
- ≥18 years of age
- Life expectancy \geq 16 weeks
- ECOG PS 0 or 1
- Adequate biliary drainage with no evidence of ongoing infection

RANDOMIZATION STRATA

Measurable Disease
Metastatic Disease



725 mg/m² cisplatin 25 mg/m²

dosing on days 1 & 8

of a 21-day cycle

NUC-1031

PRIMARY ENDPOINTS


• OS • ORR

SECONDARY ENDPOINTS

• PFS • DoR • Safety • PK • QoL

Oncologist. Epub ahead of print. oro-deoxycytidine triphosphate AE: adverse event DLT: dose-limiting toxicity ITT: intention to treat ECOG: eastern cooperative oncology group ORR: objective response rate PS: performance status


Efficacy evaluable patients




Jennifer J Knox¹, Mairéad G McNamara², Lipika Goyal³, David P Cosgrove⁴, Christoph Springfeld⁵, Katrin M Sjoquist⁶, Joon Oh Park⁷, Helena Verdaguer⁸, Chiara Braconi⁹, Paul J. Ross¹⁰, Aimery de Gramont¹¹, Rachna T Shroff¹², John R Zalcberg¹³, Daniel H. Palmer¹⁴, Juan W Valle¹

1) Princess Margaret Cancer Centre, Toronto, ON 2) University of Manchester / The Christie, Manchester, United Kingdom 3) Massachusetts ton, United States 4) Division of Medical Oncology, Vancouver Cancer Center, Compass Oncology, Vancouver, US 5) Jniversity Hospital Heidelberg, Germany 6) Cancer Care Centre, St George Hospital, Kogarah & NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia 7) Samsung Medical Center, Seoul, Republic of Korea 8) Vall d'Hebron University Hospital and Institute of Dncology (VHIO), CIBERONC, TTD Group, Barcelona, Barcelona, Spain 9) University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom 10) Guy's Hospital, London, United Kingdom 11) Franco-British Institute, Levallois-Perret, France 12) Division o Hematology/Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson 13) Monash University, Melbourne, Australia Jniversity of Liverpool, Liverpool, United Kingdor

Presentation Number **TPS351** NCT Number: NCT04163900 EudraCT Number 2019-001025-028 Email jennifer.knox@uhn.ca




NuTide:121 (Statistical Plan)



[#] DIP = Difference in observed proportions (vs. an estimated 19.0%) for statistical significance. Measu DIM = Difference in observed medians (vs. an estimated 11.7 months) for statistical significance.

NuTide:121 study sites (15 countries: ~130 sites)




SUMMARY



- Global Phase III study at ~130 sites across North America, Europe and Asia-Pacific
- NUC-1031 + cisplatin has the potential to improve survival outcomes in patients with BTC
- Further study information: NuTide121@nucana.com





Copies of this e-poster obtained through OR, AR and/or text key codes are for personal use only and may not be reproduced without written permission of the aut